Kandzari David E, Alqarqaz Mohammad, Nicholson William J, Kearney Kathleen E, Buller Christopher E, Cristea Ecaterina, Lansky Alexandra J
Piedmont Heart Institute, Atlanta, Georgia.
Henry Ford Health System, Detroit, Michigan.
J Soc Cardiovasc Angiogr Interv. 2025 Jul 22;4(7):103575. doi: 10.1016/j.jscai.2025.103575. eCollection 2025 Jul.
The Ringer perfusion catheter (Teleflex) features a novel design with a spiral-shaped inflatable balloon that approximates a hollow cylinder when inflated to manage hemorrhage associated with coronary artery perforation (CAP) during percutaneous coronary intervention while enabling distal perfusion.
In a multicenter, prospective, single-arm study, the safety and efficacy of using the Ringer device in the treatment of CAP were assessed. The primary efficacy end point included successful Ringer delivery across the perforation site, angiographic confirmation of no extravasation with balloon inflation, and demonstration of antegrade coronary flow. The primary safety end point was freedom from device-related thrombosis and coronary dissection. Clinical and angiographic outcomes were independently adjudicated.
Among 30 patients with CAP, lesion characteristics included: chronic total occlusion, 50%; severe calcification, 63.3%; lesion length 34.1 ± 23.4 mm. Ellis type II and III perforations occurred in 50% and 30% of patients, respectively. For all patients, the primary efficacy end point was 73.3% by intention to treat analysis. However, among the 26 patients with successful Ringer delivery across the perforation site, the primary end point was 84.6%. In this latter group, acute resolution of contrast extravasation was 84.6%, and maintenance of thrombolysis in myocardial infarction 2/3 antegrade flow during device inflation was 100%. No device-related safety events were observed.
Treatment of CAP with a novel perfusion balloon catheter achieved favorable rates of deliverability and reduction in hemorrhage while maintaining antegrade flow. These results demonstrate that the Ringer perfusion catheter is a safe and effective method to manage CAP until definitive treatment is decided.
林格灌注导管(泰利福公司)具有一种新颖的设计,带有螺旋形可充气球囊,充气后近似空心圆柱体,用于在经皮冠状动脉介入治疗期间处理与冠状动脉穿孔(CAP)相关的出血,同时实现远端灌注。
在一项多中心、前瞻性、单臂研究中,评估了使用林格装置治疗CAP的安全性和有效性。主要疗效终点包括林格装置成功通过穿孔部位、球囊充气后血管造影确认无外渗以及显示冠状动脉前向血流。主要安全终点是无器械相关血栓形成和冠状动脉夹层。临床和血管造影结果由独立判定。
在30例CAP患者中,病变特征包括:慢性完全闭塞,50%;严重钙化,63.3%;病变长度34.1±23.4毫米。分别有50%和30%的患者发生埃利斯II型和III型穿孔。对于所有患者,意向性治疗分析显示主要疗效终点为73.3%。然而,在26例林格装置成功通过穿孔部位的患者中,主要终点为84.6%。在后一组中,造影剂外渗的急性缓解率为84.6%,装置充气期间心肌梗死溶栓2/3级前向血流的维持率为100%。未观察到器械相关安全事件。
使用新型灌注球囊导管治疗CAP可实现良好的输送率和出血减少,同时维持前向血流。这些结果表明,在确定最终治疗方案之前,林格灌注导管是治疗CAP的一种安全有效的方法。